Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41)

The summary for the Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41): The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and participating Institutes within the National Institutes of Health (NIH) encourage small business grant applications to address different and complementary research needs for the development appropriate pediatric drug formulations in different age groups. This FOA also encourages the development and testing of novel drug delivery systems in the pediatric population. The goal of this FOA is to complement and accelerate the development of appropriate pediatric drugs formulations and drug delivery systems.

Federal Grant Title:	Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-17-200
Type of Funding:	Grant
CFDA Numbers:	93.173, 93.865
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 5th, 2020
Original Application Deadline:	January 5th, 2020
Posted Date:	March 29th, 2017
Creation Date:	March 29th, 2017
Archive Date:	February 10th, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	March 29th, 2017

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-17-200.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Medical Rehabilitation Research Resource (P50 Clinical Trial Optional); • Optimizing Health of Children and Adolescents with Perinatal HIV Exposure (U19 Clinical Tr...; • BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Centr...; • NIDCD Patient-Oriented Research Grant (R21); • Cell Lineage and Developmental Studies in Hearing and Balance; • Structural Analyses of the Ligand-Binding Properties of Taste and Smell Receptors
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...